Exclusion criteria~* Any clinically significant laboratory abnormalities on the battery of screening tests~*
Patients who in the past have not tolerated treatment with 10 mg Aricept or treatment with a corresponding dose
of another cholinesterase inhibitor~* Severe psychotic features, depression, agitation or behavioral problems
within the last three months that could lead to difficulty complying with the protocol~* Any significant
systemic illness or unstable medical condition that could lead to difficulty complying with the protocol~*
Patients who in the Investigator's opinion would not comply with study procedures~* Any significant
neurological disease other than Alzheimer's Disease, within the past five years, or with residual effects~*
Delusional symptoms are often characteristic of Alzheimer's Disease, but patients with symptoms so pronounced
that they warrant an alternative diagnosis are excluded~* History of alcohol or substance abuse or dependence
within the past two years (DSM-IV)~* History of schizophrenia (DSM-IV)~* Patients with a history of systemic
cancer within the past two years are excluded~* History of myocardial infarction in the past year or unstable
or severe cardiovascular disease, including uncontrolled hypertension~* Uncontrolled insulin-requiring diabetes
or non-insulin dependent diabetes mellitus (Haemoglobin A1c \[HBA1c\] > 10.0)~* Use of:~ * systemic
corticosteroids for more than one week within three months prior to Baseline (BL)~ * Anti-Parkinsonian agents
within two months prior to baseline (BL)~ * Approved or investigational Cholinesterase Inhibitors within 30
days or five half-lives, whichever is longer, prior to BL~ * Memantine or other N-methyl-D-aspartic acid (NMDA)
antagonists within 30 days or five half-lives, whichever is longer, prior to BL~ * Treatment with high potency
neuroleptics or narcotic analgesics within four weeks prior to BL~ * Cimetidine within four weeks prior to BL~
* Sedatives more frequently than two times per week for sleep within four weeks prior to BL
